BioStem Technologies (BioStem Technologies) Capex-to-Revenue : 0.00 (As of Sep. 2023)

View and export this data going back to 2008. Start your Free Trial

What is BioStem Technologies Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

BioStem Technologies's Capital Expenditure for the three months ended in Sep. 2023 was $0.00 Mil. Its Revenue for the three months ended in Sep. 2023 was $3.60 Mil.

Hence, BioStem Technologies's Capex-to-Revenue for the three months ended in Sep. 2023 was 0.00.

BioStem Technologies Capex-to-Revenue Historical Data

The historical data trend for BioStem Technologies's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioStem Technologies Capex-to-Revenue Chart

BioStem Technologies Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Capex-to-Revenue

Get a 7-Day Free Trial

0.20

0.05

0.01

0.07

BioStem Technologies Quarterly Data
	Sep15	Dec15	Dec16	Dec17	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Dec21	Mar22	Sep22	Dec22	Mar23	Sep23
Capex-to-Revenue	Get a 7-Day Free Trial															0.04	-	-	0.29	-

Competitive Comparison of BioStem Technologies's Capex-to-Revenue

For the Biotechnology subindustry, BioStem Technologies's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioStem Technologies's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioStem Technologies's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where BioStem Technologies's Capex-to-Revenue falls into.

BioStem Technologies Capex-to-Revenue Calculation

BioStem Technologies's Capex-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-0.469)	/	6.875
	=	0.07

BioStem Technologies's Capex-to-Revenue for the quarter that ended in Sep. 2023 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (0)	/	3.599
	=	0.00

BioStem Technologies (OTCPK:BSEM) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

BioStem Technologies Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of BioStem Technologies's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

BioStem Technologies (BioStem Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioStem Technologies Inc (OTCPK:BSEM) » Definitions » Capex-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

2836 Center Port Circle, Pompano Beach, FL, USA, 33064

Website

https://www.biostemtechnologies.com

BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Its proprietary approach, Local MicroEnvironment Activation, uses combinations of Small Molecules, Cytokines, and Growth Factors to activate the microenvironment within the body to create communication for repair in the tissue. The Company offers a comprehensive portfolio of high-quality brands that are trademarked and include RHEO, AEON, OROPRO, VENDAJE, VENDAJE AC, and VENDAJE OPTIC.